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Abstract:
Sudden cardiac death (SCD), defined as an unexpected death due to cardiac causes is the
leading cause of non-random death in young athletes (Harmon et al., 2011). Current statistics
suggest that 1 in 200,000 competitors experience SCD (Firoozi et al., 2003). Early detection of
individuals with cardiac disease, such as Hypertrophic Cardiomyopathy (HCM) and Long QT
syndrome (LQTS), can help prevent SCD, however, the heterogeneous presentation of heritable
cardiovascular conditions makes them difficult to diagnose and prognose (O’Mahony et al.,
2014). Thus, it is difficult to create universal activity restriction guidelines for at-risk athletes.
This study examines practice variation among cardiologists with regard to genetic testing of
competitive athletes for risk of SCD and subsequent activity restriction recommendations. To our
knowledge, there are no previous studies that examine these specific clinical practices among
cardiology providers. A survey was sent out through the ACC Sports and Exercise Section email
list and a University of Vermont Medical Center listserv. In total, the listservs were comprised of
~1800 cardiologists. The survey received 73 responses, 68 of which were completed in entirety.
Four knowledge-based questions were asked to create a rating scale. A significant proportion of
cardiologists answered the knowledge question regarding variants of uncertain significance
(VUS’s) incorrectly (~25%). These results suggest that physicians have some sense of
uncertainty associated with VUS’s compounded with an unfamiliarity with practice guidelines as
they relate to VUS’s. Regarding activity restriction, there is no single answer regarding
recommendations that all cardiologists chose for either LQTS scenario, a clinical diagnosis
compared to diagnosis-causing mutation and no clinical diagnosis. If a patient had a clinical
diagnosis of HCM, only half of respondents chose to strongly recommend activity restriction; we
anticipated the proportion being closer to 100%. The results indicate that there is a lack of

knowledge pertaining to VUS’s as well as a lack of consensus with regards to activity restriction
recommendations pertaining to HCM/LQTS.

Introduction:
Sudden cardiac death (SCD) is the most common cause of non-traumatic death in
athletes, accounting for 16% of deaths in this population (Harmon et al., 2011). SCD often
occurs with no prior warning, and can appear in patients who have no other clinical cardiac
findings or previous symptoms (Zheng et al., 2001). The lack of any warning signs, coupled with
low rates of revival, contributes to the high death rate of cardiac events (Zheng et al., 2001).
Startling and often unanticipated, but with a relatively high incidence rate, SCD is a major
enigma for cardiologists, emergency medicine personnel, and public health officials, not to
mention the victims and their relatives.
Competitive athletes may be particularly vulnerable to SCD due to the immense pressure
placed on them to perform during both competition and training; they may not be able to
recognize when symptoms of cardiac conditions warrant medical attention or when to end
physical activity (Barry J Maron, Zipes, & Kovacs, 2015).
The incidence of SCD in U.S. competitive college athletes ranges in report from 0.0012%
to 0.0023% (Harmon et al., 2011; Maron, Haas, Murphy, Ahluwalia, & Rutten-ramos, 2014).
However, 75% of sudden deaths during exertion were shown to be attributed to underlying
cardiac disease (Harmon et al., 2011).
In a study analyzing 1866 SCDs in young competitive athletes by Maron et al. (2009),
SCD was found to occur during or just after physical exertion 80% of the time. The other 20% of
athletes died suddenly in situations not associated with sports. The overall risk of SCD in an
NCAA student-athlete during or soon after exertion is estimated at 1 in 54,000 athletes/year

(0.0019%). The exertion-related risk of SCD in male athletes (0.0026%) is higher than the risk
for female athletes (0.00082%). African-American athlete SCD risk (0.0045%) is 3x higher than
the risk in Caucasian athletes (0.0015%) (Hainline et al., 2016; Harmon, Asif, et al., 2011).
Participation in certain sports confer higher risks than others. In order of frequency, SCD events
are most likely to occur in: basketball, football, soccer, track and field, baseball, wrestling,
swimming, and cross country (Barry J. Maron et al., 2009).
SCD is generally defined as an unexpected natural death within a relatively short time
period (usually under an hour from the onset of symptoms in an individual without any prior
lethal conditions) that is cardiac in nature (Zheng et al., 2001). Despite the fact that SCD is, by
definition, a unexpected event, there are findings, both clinical and pathologic, which suggest
that certain patients might have a predisposition for sudden cardiac events. The vast majority of
SCD events are due to malignant tachyarrhythmias, usually ventricular fibrillation (VF) or
ventricular tachycardia (VT) which devolves to VF. These tachyarrhythmias occur in individuals
with arrhythmogenic disorders, most commonly hypertrophic cardiomyopathy (HCM) and Long
QT syndrome (LQTS) (Mont et al., 2017). Although competitive athletes with HCM or LQTS
may have considerable risk with sports participation, activity restriction can cause physical and
psychological harm. Therefore, a balance must be struck between providing medical clearance
and activity restriction (Barry J Maron, Zipes, et al., 2015).
There is sizable phenotypic heterogeneity and reduced expressivity with both HCM and
LQTS, which can make diagnosing these conditions difficult. Their heterogeneous presentation
may be partially attributed to the dozens of genes and hundreds to thousands of associated
genetic variants (Caleshu & Ashley, 2017). There is debate in the literature as to the most
accurate screening method to use in order to identify true cases of LQTS and HCM, to minimize

both false positives and false negatives. For example, the use of an electrocardiography (ECG)
during preparticipation physical evaluation. The current recommendations are adequate for
detecting individuals with major symptoms of HCM and LQTS, but many patients at risk of SCD
will not experience significant symptoms. The use of an ECG during pre-participation evaluation
(PPE) would detect 75-95% of HCM cases and the majority of LQTS cases (Johnson &
Ackerman 2009; Maron & Maron, 2013). There is also debate as to what degree of athletic
participation is appropriate for individuals diagnosed with these conditions.
Given the broad and conflicting guidelines from leading cardiovascular associations, it is
not surprising that the recommendations cardiologists make for their athlete patients in practice
vary.
Hypertrophic Cardiomyopathy (HCM)
Hypertrophic cardiomyopathy (HCM) is a disease characterized by left ventricular
hypertrophy (LVH) and has broad clinical, genotypic, and phenotypic manifestations. It is a
frequent cause of SCD (Maron et al., 1995). HCM accounts for 36% of SCD in young athletes,
with a population incidence of 1/500 (Maron et al., 2009).
Risk factors for individuals with suspected or diagnosed HCM include a family history of
SCD and/or premature SCD, unexplained syncope, non-sustained ventricular tachycardia, and
abnormal blood pressure during exercise (Gollob et al., 2011). According to American College
of Cardiology/American Heart Association (ACC/AHA) guidelines, LVH that is > or = 15mm is
considered diagnostic, while 13-14mm is considered borderline (Gersh et al., 2011). Medical
management for these high-risk individuals usually includes use of an ICD (Implantable
Cardioverter Defibrillator) as well as exercise restriction, which is designed to minimize an
inducement of arrhythmia (Gollob et al., 2011).

HCM can result from genetic factors, or a combination of both. Genetically HCM is a
heterogeneous, autosomal dominant disease with thousands of mutations reported in 34+ genes.
These genes encode thick and thin contractile myofilament proteins in the sarcomere or Z-disc.
The vast majority of HCM-associated mutations occur in β-myosin heavy chain (MYH7) and
myosin-binding protein C (MYBPC3) (Barry J. Maron & Maron, 2013). However, other genes
have been implicated (Caleshu & Ashley, 2017). HCM mutations tend to be family-specific
(Barry J. Maron & Maron, 2013), but there is phenotypic variation between (Brito et al., 2003)
and within families (Menon et al., 2008). This suggest that the sarcomere mutation alone does
not determine HCM phenotype.
Long QT Syndrome (LQTS)
LQTS is a disorder that is characterized by an increased period of ventricular
repolarization, identified by a prolonged QT interval on ECG, that cannot be explained by drugs,
electrolyte imbalance, other cardiac conditions, or other factors. It includes a predisposition to
developing ventricular arrhythmias, characteristically torsades de pointes arrhythmias that can
manifest as palpitations, presyncope, syncope, seizures, or sudden cardiac arrest (Mont et al.,
2017). The 10-year mortality rate for untreated, symptomatic patients is ~ 50% (Ackerman et al.,
2011). LQTS has an estimated prevalence of 1/2000 people (Schwartz et al., 2009).
A corrected QT (QTc) interval of > or = 470ms in men and > or = 480ms in women are
considered above the 99 percentile and should prompt evaluation for LQTS (Drezner,
th

Ackerman, Cannon, et al., 2013). High risk patients are characterized by QTc >500ms (Gomez,
Prutkin, & Rao, 2016). Diagnosis should take into account ECG findings, clinical history, and
family history (Schwartz & Crotti, 2011). A family history of sudden death, especially <30 years,
unexplained drowning, vehicle accidents when the individual is driving, seizures, or sudden
infant death can raise suspicion of LQTS (Gomez et al., 2016). Despite established diagnostic

criteria, there is significant variability between heart rhythm specialists in diagnosis of LQTS. In
one study, when LQTS patients received a second opinion, 40% were reclassified as normal
(Taggart, Haglund, Tester, & Ackerman, 2007).
The mutations associated with LQTS are ones that lead to defective cardiac K+ and Na+
channels, resulting in the prolonged repolarization (Pelliccia et al., 2005). The clinical
presentation of LQTS as well as triggers of a cardiac events are gene specific (Priori et al., 2013).
There are three genes whose autosomal dominant mutations account for 70-85% of LQTS, and
are each associated with an LQTS subtype (Napolitano et al., 2005, Taggart et al., 2007).
LQTS1 (KCNQ1) patients are more likely to have an event during exercise, emotional stress,
or elevated sympathetic activity. Particular triggers for those with LQTS1 are swimming and
diving. Individuals with LQTS2 (KCNH2) tend to have events both in exercise and at rest, with
auditory stimuli being particularly triggering. Those with LQTS3 (SCN5A) are more likely to
have events during rest or sleep because their QT-interval tends to prolong at slower heart rates.
(Baars & van der Heijden, 2011; Caleshu & Ashley, 2017; Schwartz, Priori, Spazzolini, & Moss,
2001)
The incidence of cardiac arrest/SCD was found to be 20% in LQTS2 patients, 16.4% in
LQTS3 locus patients, and 10% in LQT1 patients. The pattern was similar for any cardiac event
or syncope. However, age at first event and gender did not differ between groups (Priori et al.,
2013). Interestingly, while a prolonged QT interval is a hallmark of LQTS, it is not always
present. Approximately 10-36% of patients with LQTS1-3 pathogenic mutations have normal
QTc intervals at rest (Ackerman et al. 2011; Priori et al. 2013).

Genetic Testing for LQTS and HCM
Genetic Testing is recommended for anyone with a clinical diagnosis of LQTS and HCM,

but identifying a pathogenic mutation can be very challenging (Kumar and Elliott, 2010). While
the genes associated with LQTS and HCM have been identified, there can be many different
pathogenic mutations within these genes (Löllgen and Löllgen, 2012). Even when a mutation is
reported, it possible that this is the first time this specific variant has been identified in a gene
associated with LQTS or HCM, in effect a family specific mutation, so it is difficult to determine
whether the variant is pathogenic or benign, especially in a phenotypically negative individual
(someone showing no clinical features) (Kumar and Elliott, 2010).
While using through rapid, automated, DNA sequencing to look for pathogenic mutations
for HCM and LQTS is possible, it is not very practical as fewer than 50% of clinically affected
patients test positive for a known pathogenic mutation due to the heterogeneity. This means that
the results of DNA-based testing frequently result in a VUS, which would provide virtually no
clinical utility to the patient or the patient’s family. (Maron and Maron, 2013) Furthermore, even
if a patient is genotype positive, the majority (HCM) or nearly half (LQTS) of patients will be
asymptomatic due to reduced penetrance. In fact, in the case of HCM, if a patient is genotype
positive, phenotype negative, and lacks a significant family history of SCD; then it appears the
risk of SCD for that patient is extremely low and is likely no different from the risk in the
general population. (Maron et al., 2015)
If a pathogenic mutation is identified in a phenotype positive patient, it can be used as a
“predictive” gene test for other members of that family (Kumar and Elliott, 2010). That being
said, a negative result for this mutation can also lead to uncertain results. It is common, in both
LQTS and HCM, for there to be more than one disease causing mutation present within one
family (Kumar and Elliott, 2010). For example, it is possible for a sibling to have a different
pathogenic mutation in the same or another gene after testing negative for the pathogenic

mutation identified in the affected sibling.
For these reasons, genetic testing may not act as a reliable method to screen individuals
for HCM and LQTS. Nevertheless, the conditions are genetically linked and are passed in an
autosomal dominant fashion, and so a detailed family history can act as a key tool for identifying
at risk individuals. An ECG and an echocardiography should be performed regularly on
individuals believed to be at risk and on family members of affected individuals (Enriquez and
Goldman, 2014).
Return to Play and Activity Restriction Guidelines
The 2015 Eligibility and Disqualification Criteria for Athletes With Cardiovascular
Abnormalities guideline from the AHA/ACC informs the competitive athlete cardiovascular
sports participation landscape (Barry J Maron, Zipes, et al., 2015; Pelliccia et al., 2005). The
document cautions that it is a general guideline aimed to aid physicians with activity restriction
decisions; it is not precise advice for individual cases and should therefore help inform but not
replace the judgment of the physician (Mitten, Zipes, Maron, Bryant, & Heart, 2015; Pelliccia et
al., 2005). The guideline aims to balance the risks and benefits of participation in competitive
sports, and to not simply restrict all activity in at-risk athletes.
AHA/ACC guideline provides recommendations for HCM and LQTS. For HCM, the
ACC/AHA recommends that probable or unequivocally symptomatic athletes (i.e. manifesting
LVH) should not participate in competitive sports, except low-intensity sports. This
recommendation is independent of age, sex, magnitude of LV hypertrophy, particular sarcomere
affected by the mutation, presence or absence of LV outflow obstruction (at rest or with
physiological exercise), absence of prior cardiac symptoms, presence or absence of late
gadolinium enhancement (fibrosis) on CMR, and whether or not major interventions such as
surgery have been performed previously. The ACC/AHA guideline states that for athletes who

are G+/P-, participation in competitive athletics is reasonable, especially if there is no family
history of HCM-related SCD. The ACC/AHA also advises that pharmacological agents and
ICDs should not be administered or placed in athletes for the sole purpose of allowing them to
participate in high-intensity sports (Barry J Maron, Udelson, et al., 2015).
With regard to LQTS, the AHA/ACC recommends that athletes who are suspected to
have or who are diagnosed with LQTS undergo a comprehensive evaluation by a heart rhythm
specialist or genetic cardiologist with sufficient experience and expertise. When symptomatic
athletes are suspected to have or are diagnosed with LQTS, it is recommended that they be
restricted from all competitive sports until a comprehensive evaluation has been completed, the
athlete and his/her family are well-informed, treatment has been initiated, and the athlete has
been asymptomatic for 3 months. For an athlete with either symptomatic LQTS or
electrocardiographically manifest LQTS (corrected QT interval >470 ms in males or >480 ms in
females), competitive sports participation (except competitive swimming in a previously
symptomatic LQT1 individual) may be considered after treatment, given appropriate
precautionary measures, and assuming that the athlete has been asymptomatic on treatment for at
least 3 months. The AHA/ACC guideline states that it is reasonable for a G+/P- LQTS athlete to
participate in competitive sports if they avoid QT-prolonging drugs, ensure electrolyte/hydration
replenishment, avoid dehydration, avoid or treat hyperthermia from febrile illnesses or trainingrelated heat exhaustion or heat stroke, acquire a personal automatic external defibrillator as part
of the athlete’s personal sports safety gear, and establish an emergency action plan with the
school or team officials (Ackerman et al., 2015).
The ultimate decision on activity restriction is a complex balance of the athlete’s
individual liberties, physician’s legal liabilities, and third-party (coaches, schools) interests.

Although the ultimate goal is to prevent SCD, it is unfair to unnecessarily prevent athletes from
competitive sports or a healthy lifestyle (Barry J Maron, Zipes, et al., 2015). According to a
consensus statement from the ACC and NCAA, the NCAA holds each individual
school/institution responsible for protecting the health and safety of the athletes. Further, the
management of cardiac disorders and all sport eligibility decisions or RP/AR are ultimately the
responsibility of team’s health care providers in conjunction with cardiology specialists
(Hainline et al., 2016).
Recommendations for handling athletes with confirmed or suspected HCM or LQTS are
complex and sometimes contradictory. This study examines practice among cardiologists with
regard to genetic testing of competitive athletes for risk of SCD, and how cardiologists handle
issues of return to play among competitive athletes who are at risk based on clinical examination
and/or genetic testing. To our knowledge, there are no previous studies looking at either of these
questions.

Methods:
Participants
Participants in this study were practicing cardiologists working both in general practice
and specialty settings. Cardiologists were contacted through The ACC Sports and Exercise
Section listserv and a University of Vermont Medical Center listserv. In total, the listservs are
comprised of ~1800 cardiologists. Two e-mails were sent to each listerserv: an initial e-mail and
one reminder e-mail. Interested participants gave informed consent online prior to the beginning
of the survey. The survey received 73 responses, 68 of which were completed in entirety. This
study received IRB approval on 1/23/18 prior to the survey distribution.

Procedures

A voluntary and confidential survey was developed on surveymonkey.com. Participants
were asked to answer general demographics questions and rate their opinions on a variety of
topics relating to knowledge of genetics, recommendations, and their experiences in practice.

Data Analysis
Frequency statistics were generated for demographics and Likert scales questions. Chisquare tests were conducted to determine statistically significant relationships between genetics
knowledge and working with genetics professionals, ordering testing, results disclosure, and
demographics. Practices with regard to use of pedigree construction were also analyzed. We
examined the course of action participants would take in 4 clinical scenarios (clinical
manifestation of HCM, genotype positive-phenotype negative for HCM, clinical manifestation of
LQTS, and genotype positive-phenotype negative for LQTS) and the relationship between
NCAA employment and results communication, hesitation to perform genetic testing, and course
of action.
All qualitative data and open-ended questions were downloaded from
surveymonkey.com. The data was loaded into Statistical Package for the Social Sciences (SPSS)
Statistics, a software program used for statistical analysis. An independent experienced
qualitative analyst reviewed the data to determine appropriateness and significance. Crosstabs,
chi-square tests, and one-way ANOVA assessed differences in mean scores, and correlations of
two continuous variables. A p-value of less than 0.05 was considered significant.

Results:
Demographics
The survey was distributed to over 1800 cardiologists from multiple specialties and
locations throughout the United States). From this cohort, 73 cardiologists completed the survey.
The majority of respondents were general practice cardiologists (39.73%, n=29). A similar

proportion of the cardiologists surveyed were specialists in electrophysiology (19.28%,n = 14),
sports cardiology (15.07% n=11), or other (17.81%, n=13). Of the other category, the majority
were pediatric cardiologists (n=7). The final category was specialist in heart
failure/cardiomyopathy, which consisted of 8.22% (n=6) of the subset. (Figure 1)
The majority of the individuals sampled worked at an academic medical center (63.89%,
n=46). A similar proportion of the cardiologist's reported working in a private practice (16.67%,
n=12), or a community hospital (13.89%, n=10). The remaining 4 cardiologists (5.56%) selected
the other category. (Figure 1)
When asked how often the cardiologist sees competitive athletes under the age of 25,
over 78% of respondents replied either regularly (38.36%, n=28), or occasionally (39.73%,
n=29). A similar proportion of the cardiologists reported seeing this set of patients frequently
(9.59%, n=7), compared to rarely/never (12.33%, n=9).

Knowledge of Cardiovascular Genetics

Four knowledge-based questions were asked to create a rating scale. All 73 cardiologists
that participated in the survey responded to these questions in entirety. Most, 94.5% (n=69) knew
that patients with hereditary cardiovascular conditions may have a completely negative family
history for the same condition. In comparison, 75.3% (n=18) of cardiologists knew that a variant
of uncertain significance (VUS) found by genetic testing for hereditary cardiovascular conditions
cannot be used to make medical management decisions. Almost everyone, 91.8% (n = 67) knew
that a VUS found by genetic testing for hereditary cardiovascular disease should not be treated as
pathogenic (disease-causing) until otherwise specified (question 7). Likewise, 93.2% knew that
negative genetic testing in a patient with a suspected hereditary cardiovascular condition rules
out a diagnosis for that specific condition. (Figure 2)

Based on the responses to the four questions, a knowledge score was created where a
score of one was given for each correct answer. The total score is reported below:

Number of Cardiologists

Score (out of 4)

67.1% (49)

4

23.3% (17)

3

8.2% (6)

2

1.4% (1)

0

The mean score was 3.55 (Std. Dev. = .76), and the median and mode were 4.0.
Respondents were separated into 2 categories: those who answered all questions correctly, 67.1%
(n=49), and those who answered less than 4 questions correctly 32.9% (n=24). This was done
due to the limited sample size of this study.
When asked, “A VUS is best presumed…” 95.59% of respondents answered
“Inconclusive – report to the patient with an explanation of inconclusive results.” There were 3
outliers. Of these, one cardiologist said that a VUS is presumed to be disease-causing and two
said “inconclusive-do not report to patients.” None of the three were specialist cardiologists.
Two of the three were general cardiologists and one was working in research and evaluation.

Working with Genetics Professionals
Genetic counselors and/or geneticists are the genetics providers physicians tend to refer
patients to regarding genetic conditions and/or genetic testing. 19.44% (n=14) of cardiologists
report working with or referring to a genetic counselor frequently, 30.56% (n=22) reported
regularly, 27.78% (n=20) reported occasionally, and 22.22% (n=16) reported rarely/never
working with or referring to a genetic counselor.

There was a significant difference in the knowledge score between cardiologists who
ordered the initial genetic testing themselves and those who referred patients to genetic
counselors, geneticists, or a genetic nurse for initial testing (Chi-square = 5.03, (df=1) p<.05).
44.44% (n=32) refer their patients to genetic counselors, 1.39% (n=1) refer their patients to
genetic nurses, 15.28% (n=11) refer their patients to geneticists, while 30.56% (n=22) order the
genetic testing themselves.
There was also a relationship between how often the cardiologist works with or refer to a
genetic counselor and knowledge (t (70) = 3.93, p<.001). Cardiologists who answered all 4
questions correctly tended work with genetic counselors frequently, while those who answered
less than 4 questions correctly tended to work with genetic counselors occasionally.

Knowledge of Who Orders Initial Genetic Testing
86.4% (n=19) of those who ordered genetic testing themselves answered all questions
correctly, while 59.1% (n=26) of those who referred the patients to genetics for testing answered
all questions correctly. (Figure 3)

Knowledge and Disclosing results
Answering all questions correctly was not associated with practice in terms of disclosing
the results of the testing to patients (Chi-square = .07, (df=1), p=.79, n.s.). Almost the same
number of cardiologists who disclosed the results themselves (64.5%) and those who referred the
patient to a genetic counselor, a geneticist or a genetic nurse (67.6%), answered all the questions
correctly.

Cardiologists who order the genetic testing themselves also tend to disclose the results to
patients (Chi-square = 11.81 (df=1), p<.01). 80.0% (n=16) of those who order the testing
themselves also disclose results to patients, while only 33.3% of those who refer to genetics for
testing disclose the results to patients. In total, 45.2% (n=28) refer to genetics for testing and
refer to genetics for results; 25.7% (n=16) order the testing and disclose the results themselves;

22.6% (n=14) refer for testing but disclose the results themselves, and 6.5% (n=4) order the
testing but refer the patients to genetics for results. (Figure 4)

Knowledge and Demographics
The knowledge category was not related to workplace setting, whether or not the
cardiologist was employed in an NCAA school, or how often the cardiologist saw competitive
athletes under the age of 25.

Family History
With regard to construction of pedigrees, 16.6% of respondents indicated that they
always construct a pedigree, 31.94% construct a pedigree frequently on a case-specific basis,
37.5% rarely construct a pedigree on a case-specific basis, and 13.89% never construct a
pedigree. Of the respondents who do construct pedigrees, 9.84% only ask about parents and
siblings, 49.18% ask about siblings, parents, aunts, uncles and grandparents, and 40.98% also ask
about cousins.
There was a significant positive correlation between how often cardiologists construct a
pedigree when asking about a family medical history and how often they work with or refer to a
genetic counselor (r (71) = .31, p<.01)

The frequency of working with a genetic counselor was not related to how many
generations the cardiologist asks about when constructing a pedigree (Table 1, F = 2.51, p =
.09,n.s.) Those who asked about parents, siblings, aunts, uncles, grandparents and cousins had
slightly more contact with genetic counselors than those that asked about fewer family members
with a mean score of 2.12, the equivalent of regularly. However, the difference was not
statistically significant.

Course of Action

For a clinical diagnosis of LQTS, 38.24% (n=26) of respondents would strongly
recommend activity restriction (no competitive athletics), 35.29% (n=24) would suggest activity
restriction (no competitive athletics) but support the athlete’s decision if they choose to
participate, none of the respondents would make no recommendation as to competitive athletics
and 26.47% (n=18) would choose other courses of action. Some of the other courses of action
included: referring the patient to an electrophysiologist, allowing participation if precautionary
measures are met, requiring more information about LQTS subtype and history, utilizing joint
decision making, and referring to guidelines. (Figure 4)
If a patient does not have a clinical diagnosis of LQTS but does have a pathogenic
mutation, 7.35% (n=5) of respondents strongly recommend activity restriction, 44.12% (n=30)
suggest activity restriction but support the athlete’s decision if they choose to participate, 16.18%
(n=11) make no recommendation as to competitive athletics, and 32.35% (n=22) would take
another course of action. Some of the other courses of action include: taking into account LQTS
subtype, further testing to identify intermittent LQTS, and allow the patient to play if on beta
blockers and an emergency action plan is in place, referring to guidelines, and referring the
patient to an electrophysiologist. (Figure 4)
Because many respondents answered that they would refer to an electrophysiologist for
the LQTS recommendation questions, we also examined the answers from electrophysiologists
exclusively. Electrophysiologists (25.87%, n=14) strongly recommend activity restriction,
42.86% Suggest activity restriction (no competitive athletics) but support the athlete’s decision if
they choose to participate, none chose to make no recommendations, and 28.57% would chose
“other”. Their explanations of their course of action include: following guideline
recommendations, discussing ramifications/guidelines and doing joint decision making, depends

on LQTS subtype and clinical history, and allow to play assuming emergency action plan, takes
beta blockers, and receives ICD if the patient meets clinical criteria.
Of the electrophysiologists, if a patient does not have a clinical diagnosis of LQTS but
does have a pathogenic mutation, 7.14% (n=1) strongly recommend activity restriction, 28.57%
(n=4) suggest activity restriction but support the athlete’s decision if they choose to participate,
28.57% (n=4) make no recommendation as to competitive athletics, and 35.71% (n=5) would
take another course of action. Some of the other courses of action include: taking into account
LQTS subtype, further testing to identify intermittent LQTS, and allow the patient to play if on
beta blockers and an emergency action plan is in place.
If a patient has a clinical diagnosis of HCM, 52.24% (n=35) of respondents would
strongly recommend activity restriction (no competitive athletics), 34.32% (n=23) would suggest
activity restriction (no competitive athletics) but support the athlete’s decision if they choose to
participate, 2.99% (n=2) would make no recommendations as to competitive athletics, 10.44%
(n=7) would choose other courses of action. Some of the other courses of action include: their
recommendations depend on HCM phenotype, said they would allow [the athlete] to play
assuming emergency action plans, stays well hydrated, receives ICD if meets clinical criteria,
and follows guidelines. (Figure 4)
If a patient does not have a clinical diagnosis of HCM but does have a pathogenic
mutation, 7.46% (n=5) strongly recommend activity restriction, 32.84% (n=22) suggest activity
restriction but support the athlete’s decision if they choose to participate, 31.34% (n=21) make
no recommendation as to competitive athletics, and 28.36% (n=19) would take another course of
action. Some of the other courses of action include: stratifying risk, close follow-up, allow

participation with close surveillance, and further determining risk based on specific mutations.
(Figure 5)

Generalist vs. Specialist
There were no significant differences between generalist and specialist cardiologists and
the recommendations they would give with a clinical diagnosis of LQTS, a disease-causing
mutation of LQTS, a clinical diagnosis of HCM, or a disease-causing mutation of HCM. There
were no significant differences between generalist and specialist cardiologists and what the
cardiologist thought was sufficient to merit ordering genetic testing for LQTS or HCM.
Likewise, there were no significant differences between how frequently the cardiologist referred

to a genetic counselor and what they thought was sufficient to order genetic testing for LQTS or
HCM.
These was a significant difference between the knowledge category of general practice
cardiologists and specialist cardiologists (Figure 4) (Chi-square = 4.49 (df=1), p<.05). While
80.6% (25) of specialists answered all 4 questions correctly, only 55.2% (n=16) of general
practice cardiologists answered all 4 questions correctly. While 44.8% (n=13) of general practice
cardiologists answered only 0-3 questions correctly, only 19.4% (n=6) of the specialists
answered less than 4 questions correctly. (Figure 6)

Being Employed by an NCAA School

23.61% (n=17) of respondents reported being employed in some capacity by an NCAA
school. Being employed by an NCAA school was not associated with any significant difference
in respondents’ reported practices in terms of giving results to coaches, parents or other parties
when there is a clinical diagnosis of LQTS or HCM. 64.7% (n=11), of those with an NCAA
affiliation would communicate results directly back to the referring physician, while 54.5%
(n=30) of those without an NCAA affiliation would communicate results directly to the referring
physician. (Figure 7)
Being employed by an NCAA school was associated with no significant difference in
how people, other than the patient, would be informed if a disease-causing mutation was
identified for LQTS or HCM, but no clinical features were present. (Figure 7)
There were no significant differences between whether or not the cardiologist would
hesitate to perform genetic testing for LQTS or HCM due to potential consequences of having
this information in their medical records and their affiliation with an NCAA school. In addition,
there was no significant difference between the respondent’s reported course of action in the
event of a diagnosis or positive genetic testing results and their affiliation with an NCAA school.

Discussion:
Misapprehensions Regarding Variants of Uncertain Significance (VUS)
Four knowledge based questions were asked in order to assess the underlying genetics
knowledge of our cohort as it pertains to understanding the intricacies involved in interpreting
pathogenicity of genetic variants for HCM and LQTS. As expected, the majority of cardiologists
knew that patients with hereditary cardiovascular conditions may have a completely negative
family history for the same condition. The question requires respondents to demonstrate an
understanding of the concept of reduced/age dependent penetrance in cardiovascular conditions,
and/or the possibility of a de novo mutation that would not present in the family history. The four
individuals who answered incorrectly were statistical outliers; three of these cardiologists were
general practitioners and one was a cardiology fellow.
While the majority of cardiologists understood the relationship between family history
and HCM/LQTS (94.52%, n=69), fewer understood that a VUS found by genetic testing for
hereditary cardiovascular conditions could not be used to make medical management decisions
(75.34%, n = 55). One possible explanation is that cardiologists simply do not have adequate

training in genetics and therefore do not fully understand the limitations of clinical application of
an identified VUS.
Previous studies have shown that genetics education is a limited part of the medical
school curriculum (Burke, Stone, Bedward, Thomas, & Farndon, 2006). Burke specifically
looked at four medical specialties: family practice, neurology, cardiology, and dermatology and
found that training in genetics was insufficient according to student reports. Alarmingly, 12
students out of the cohort reported that they only received a few hours of instruction with regard
to genetics. Another study found a significant lack of genetics preparation for the provider
community. The study cites a recent survey by the American Medical Association and Medco,
which found that the majority of medical schools have only just begun to institute genetics
training curriculum for their students. They also indicated that only 29% of current practicing
physicians report any training in genetics (Marchant, G.E., Lindor, R.A., 2013).
Although genetics is making its way into mainstream practice (Marchant, G.E., Lindor,
R.A., 2013), given this background it is not surprising that a there is a gap in the knowledge of
our cohort of cardiologists, especially when it comes to complex genetic concepts such as the
VUS. At first glance, such a response would indicate that these physicians do not adequately
understand the nuances of a VUS, due to their lack of training and/or underlying knowledge of
variant analysis. Though concern over liability is feasible, it seems less likely that this concern
informed the physician response in this hypothetical scenario.
Although 24.7% (n=18) of cardiologists said that medical management decisions can be
made based on a VUS, of that group, only 6 cardiologists did not know that a VUS found by
genetic testing for a hereditary cardiovascular disease should not be treated as pathogenic. This
discrepancy further strengthens the argument that perhaps most of the cardiologists actually do

understand the limitations of clinical application of a genetic variant with uncertain
pathogenicity. However, medical management decisions do not necessarily correlate with
knowledge, as there are outside forces that influence cardiologists to make other decisions that
are not necessarily supported by scientific evidence.
It is interesting to note that all three of the cardiologists with incorrect answers to
question 19, the fill-in statement “A VUS is best presumed…”, had correct answers to the
question indicating that it was false that ‘a VUS found by genetic testing for hereditary
cardiovascular conditions, can be used to make medical decisions’. One of the three who said
that a VUS is best presumed to be disease causing also had an incorrect answer to the question
saying that it was false that a VUS found by genetic testing for hereditary cardiovascular disease
conditions should be treated as pathogenic until otherwise specified. The two cardiologists who
said a VUS is presumed to be “inconclusive - do not report to the patients” answered correctly
that treating the VUS as pathogenic was false.” Since these cardiologists are outliers, no
statistical conclusions can be drawn from their statements.
Cardiologists’ Recommendations: Inconsistencies in Practice
For athletes with a clinical diagnosis of LQTS, a similar proportion of cardiologists chose
the options of strongly recommending activity restriction or suggesting activity restriction, but
also supporting the athlete’s decision if they choose to participate. The lack of consensus
regarding activity restriction recommendations for LQTS is also reflected in the literature.
Among athletes with phenotypic LQTS who continued to play in competitive sports, only 1/60 of
them experienced a sentinel event (Johnson & Ackerman, 2013). Additionally, data indicates that
athletes with ICDs can continue to play with negligible mortality (0 deaths within 31 months
follow-up) (Lampert et al., 2013).

According to the 2015 AHA/ACC guidelines, athletes who are suspected to have or who
are diagnosed with LQTS should undergo a comprehensive evaluation by a heart rhythm
specialist or genetic cardiologist with sufficient experience and expertise. The AHA/ACC
guidelines further state that competitive sports participation (except competitive swimming in a
previously symptomatic LQT1 individual) may be considered after treatment, given appropriate
precautionary measures, and assuming that the athlete has been asymptomatic on treatment for at
least 3 months (Ackerman et al. 2015). Therefore, cardiologists who chose the “other” option
and recommended referring to an electrophysiologist or would likely allow participation if
precautionary measures are met are within the bounds of the guideline recommendations. To
add, although one could go even further and infer that perhaps it is inappropriate for cardiologists
to make any activity restrictions at all if the patient has been asymptomatic for an adequate
amount of time with appropriate precautionary measures in place.
If a patient does not have a clinical diagnosis of LQTS but does have a pathogenic mutation,
the majority of respondents suggest activity restriction but ultimately support the athlete if they chose
to play. The least popular answer was strong recommendation of activity restriction. The AHA/ACC
guideline states that it is reasonable for a genotype-positive/phenotype-negative LQTS athlete to
participate in competitive sports if they take the recommended precautionary measures (Ackerman et
al., 2015). Therefore, our finding that strongly recommending activity restriction is the least preferred
choice among cardiologists for athletes with an LQTS pathogenic mutation but no clinical diagnosis
is not surprising; a strong recommendation to discontinue competitive sports is likely unwarranted in
this setting. Further, in a study following 70 athletes with genotype-positive, phenotype-negative
LQTS who participated in competitive sports, none of them had a sentinel event during play (Johnson
& Ackerman, 2013). Our finding that supporting the athlete if they choose to participate makes sense

in the context of the literature. In general, there is a lack of data regarding the risk of an athlete with a
LQTS has by competing in competitive sports (Ackerman et al. 2015). Therefore, genotype-positive,
phenotype-negative athletes introduce even more uncertainty. If SCD or sentinel events are unlikely
for genotype-positive, phenotype-negative LQTS athletes, then it makes sense to support an athlete if
they choose to play. It is also in line with expectation that many cardiologists chose to elaborate on
their thoughts by choosing “other”, as there are many different considerations and nuances to an
athlete’s fitness to play in this scenario.
In athletes with a clinical diagnosis of HCM, the majority of respondents would strongly
recommend activity restriction (52.24%), with a smaller proportion opting to suggest activity
restriction (32.84%) but support the athlete if they choose to participate. The ACC/AHA
recommends that symptomatic athletes should not participate in competitive sports, except lowintensity sports. This recommendation is independent of age, sex, magnitude of LV hypertrophy,
particular sarcomere affected by the mutation, presence or absence of LV outflow obstruction (at
rest or with physiological exercise), absence of prior cardiac symptoms, presence or absence of
late gadolinium enhancement (fibrosis) on CMR, and whether or not major interventions such as
surgery have been performed previously (Maron et al. 2015). Given the explicit recommendation
that athletes with a clinical diagnosis of HCM should not participate in competitive sports, it is
not surprising that the vast majority of cardiologists strongly recommend activity restriction.
However, it is surprising that with such definitive guidelines, only half of respondents chose to
strongly recommend activity restriction; we anticipated the proportion being closer to 100%. To
add, 2.99% of cardiologists make no recommendation with regards to competitive sports
participation. This is surprising because the guideline is quite unambiguous. Furthermore,
respondents seem less certain of their response here than they did with LQTS, although

guidelines for LQTS provide more room for clinical judgment. Although risk-stratification is
encouraged in order to determine HCM SCD probability and treatment plan (Gersh et al. 2011),
it is not part of of ACC/AHA Eligibility and Disqualification Recommendations for Competitive
Athletes in order to determine return to play eligibility. These responses are in contrast with
ACC/AHA guidelines as particular sarcomere affected by the mutation, absence of LV outflow
obstruction, absence of prior cardiac symptoms, absence of fibrosis, and interventions should not
impact competitive athletic recommendation if a patient has unequivocal or probable HCM
(Maron et al. 2015).
In patients with a clinical diagnosis of HCM without a pathogenic mutation, most
cardiologists in this sample would support of the athlete’s decision if they choose to participate
or offer no recommendation regarding competitive athletics. The ACC/AHA guideline states that
for athletes who are genotype-positive, phenotype-negative, participation in competitive athletics
is reasonable especially if there is no family history of HCM-related SCD (Maron et al. 2015).
Therefore, our finding that strongly recommending activity restriction for these athletes is the
least likely course of action for cardiologists, is in line with expectation. Interestingly, although
ACC/AHA guidelines specifically mention evaluating the family history in this situation, none of
the respondents commented on examining family history for SCD and incorporating that into
their activity restriction decision-making. However, we found that 48.54% of respondents
indicated they always or frequently construct pedigrees. Therefore, it is possible that the
cardiologists examine family history in the initial work-up in order to determine if a genetics
evaluation or testing is warranted, but do not revisit family history information when providing
activity restriction recommendations. One respondent stated that they would “[a]llow [the
athlete] to play assuming emergency action plan [is in place] and [the athlete] stays well

hydrated.” This response was unexpected as environmental factors are not commented on in the
ACC/AHA 2015 guidelines for HCM.

Limitations:
A recurrent limitation in this study was the small sample size. Specifically, when
considering our two knowledge categories (all 4 correct vs. 3 or less correct). Originally, we
wanted this to be a knowledge score, but this became illogical as only 7 cardiologists answered
2-0 questions correctly. Additionally, when comparing cardiologists affiliated with an NCAA
school and cardiologists not affiliated with an NCAA school, we had a very small sample of
cardiologists affiliated with an NCAA school. Final, our findings regarding family history was
almost significant. With a larger sample size, it is possible these differences could be found
significant.
We also believe that using specific case scenarios would have helped us better understand
the intricacies of how a given cardiologist might make decisions about treatment, diagnosis, and
recommendations with regards to HCM and LQTS. We observed that some cardiologists were
not able to answer the survey questions properly because there were not enough details in the
questions. For example, many cardiologists chose to elaborate on their thoughts by choosing
“other”, because there are many different considerations and nuances to an athlete’s fitness to
play in any given scenario.

Conclusion:
The majority of cardiologists have some understanding of the nuances of genetic testing
for inherited cardiovascular conditions however, this study suggests that cardiologists are
uncertain of the clinical application of a VUS associated with an inherited cardiovascular
condition and vary considerably in how VUS is used in clinical practice to make medical

management recommendations. Reported practice by this cohort of cardiologists demonstrates
significant variability in recommended activity restriction in individuals with a diagnosis of
LQTS and individuals with an inherited predisposition to LQTS but without definitive
phenotypic disease which reflects the lack of consensus in the available literature regarding best
practices for individuals with LQTS. Although HCM activity restriction guidelines definitively
state that athletes with a clinical diagnosis of HCM should not participate in competitive
athletics, only half of respondents chose to strongly recommend activity restriction. For athletes
with genotype-positive, phenotype-negative HCM, our finding that strongly recommending
activity restriction for these athletes is the least likely course of action for cardiologists, is in line
with expectation.

Acknowledgements:
The authors would like to thank Dr. Smith for his assistance in the data analysis for the study,
Laura Hercher and Samantha Freeze for their donation of the study incentive, and all the
participants that made this study possible. This manuscript is based on a research project
conducted by Tamar Ailenberg, Samone Schneider and Anna Schon Levy in 2018 to fulfill the
requirements of the Sarah Lawrence College Master’s degree in Human Genetics
Conflict of Interest
Tamar Ailenberg, Samone Schneider and Anna Schon Levy declare that they have no conflict of
interest.
Informed Consent
Professors Claire Davis and Elizabeth Johnston of the Sarah Lawrence College IRB, approved
this study prior to any recruitment. All procedures followed were in accordance with the ethical
standards of the responsible committee on human experimentation (institutional and national)

and with the Helsinki Declaration of 1975, as revised in 2000 (5). Informed consent was
obtained from all patients for being included in the study.

References
Ackerman, M. J., Priori, S. G., Willems, S., Berul, C., Brugada, R., Calkins, H., … Olson, S. (2011). HRS/EHRA
expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Europace,
13(8), 1077–1109. https://doi.org/10.1093/europace/eur245
Ackerman, M. J., Zipes, D. P., Kovacs, R. J., & Maron, B. J. (2015). Eligibility and Disqualification
Recommendations for Competitive Athletes With Cardiovascular Abnormalities : Task Force 10 : The Cardiac
Channelopathies and American College of Cardiology. Circulation, 132(22), 326–330.
https://doi.org/10.1161/CIR.0000000000000246
Baars, H. F., & van der Heijden, J. F. (2011). Congenital Long QT-Syndrome. In H. F. Baars, P. A. F. M.
Doevendans, & J. J. van der Smagt (Eds.), Clinical Cardiogenetics (pp. 143–164). London: Springer-Verlag.
Brito, D., Richard, P., Isnard, R., Pipa, J., Komajda, M., & Madeira, H. (2003). Miocardiopatia Hipertrófica
Familiar : INTRODUCTION. Revista Portuguesa de Cardiologia, 22(12), 1445–1461.
Burke, S., Stone, A., Bedward, J., Thomas, H., & Farndon, P. (2006). A “neglected part of the curriculum” or “of
limited use”? Views on genetics training by nongenetics medical trainees and implications for delivery. Genetics In
Medicine, 8, 109. Retrieved from http://dx.doi.org/10.1097/01.gim.0000200159.19920.b5
Caleshu, C., & Ashley, E. (2017). 17 Genetic Testing for Cardiovascular Conditions Predisposing to Sudden Death,
175–186.
Christiaans, I., Leakanne dit Deprez, R. H., van Langen, I. M., & Wilde, A. A. M. (2009). Ventricular fibrillation in
MYH7-related hypertrophic cardiomyopathy before onset of ventricular hypertrophy. Heart Rhythm, 6(9), 1366–
1369. https://doi.org/http://dx.doi.org/10.1016/j.hrthm.2009.04.029
Enriquez, A. D., & Goldman, M. E. (2014). Management of hypertrophic cardiomyopathy. Annals of global health,
80(1), 35-45.
Firoozi, S., Sharma, S., & McKenna, W. J. (2003). Risk of competitive sport in young athletes with heart
disease. Heart, 89(7), 710-714. http://dx.doi.org/10.1136/heart.89.7.710
Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., … Yancy, C. W. (2011). 2011
ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: A report of the American
College of cardiology foundation/American heart association task force on practice guidelines. Circulation, 124(24).
https://doi.org/10.1161/CIR.0b013e318223e2bd
Gollob, M. H., Blier, L., Brugada, R., Champagne, J., Chauhan, V., Connors, S., ... & Harris, L. (2011).
Recommendations for the use of genetic testing in the clinical evaluation of inherited cardiac arrhythmias associated
with sudden cardiac death: Canadian Cardiovascular Society/Canadian Heart Rhythm Society joint position
paper. Canadian Journal of Cardiology, 27(2), 232-245. https://doi.org/10.1016/j.cjca.2010.12.078
Gomez, A. T., Prutkin, J. M., & Rao, A. L. (2016). Evaluation and Management of Athletes With Long QT
Syndrome. Sports Health, 8(6), 527–535. https://doi.org/10.1177/1941738116660294
Hainline, B., Drezner, J. A., Baggish, A., Harmon, K. G., Emery, M. S., Myerburg, R. J., … Thompson, P. D.
(2016). Interassociation Consensus Statement on Cardiovascular Care of College Student-Athletes. Journal of the
American College of Cardiology, 67(25), 2981–2995. https://doi.org/http://dx.doi.org/10.1016/j.jacc.2016.03.527

Harmon, K. G., Asif, I. M., Klossner, D., & Drezner, J. A. (2011). Incidence of sudden cardiac death in national
collegiate athletic association athletes. Circulation, 123(15), 1594–1600.
https://doi.org/10.1161/CIRCULATIONAHA.110.004622
Johnson, J. N., & Ackerman, M. J. (2009). QTc: how long is too long?. British journal of sports medicine, 43(9),
657-662. http://dx.doi.org/10.1136/bjsm.2008.054734
Johnson, J. N., & Ackerman, M. J. (2013). Return to play? Athletes with congenital long QT syndrome. Br J Sports
Med, 47(1), 28-33. http://dx.doi.org/10.1136/bjsports-2012-091751
Kumar, D., & Elliott, P. (2010). Principles and practice of clinical cardiovascular genetics. Oxford University
Press, USA.
Lampert, R., Olshansky, B., Heidbuchel, H., Lawless, C., Saarel, E., Ackerman, M., … Cannom, D. (2013). Safety
of Sports for Athletes With Implantable Cardioverter-Defibrillators, 2021–2031.
https://doi.org/10.1161/CIRCULATIONAHA.112.000447
Löllgen, H., & Löllgen, R. (2012). Genetics, genetic testing and sports: Aspects from sports cardiology. Genomics,
Society and Policy, 8(1), 1-16. https://doi.org/10.1186/1746-5354-8-1-32
Marchant, G. E., & Lindor, R. A. (2013). Personalized Medicine and Genetic Malpractice. Genetics in Medicine :
Official Journal of the American College of Medical Genetics, 15(12), 921–922.
http://doi.org/10.1038/gim.2013.142
Maron, B., Haas, T., Ahluwalia, A., & Rutten-Ramos, S. (2013). Incidence of cardiovascular sudden deaths in
Minnesota high school athletes. Heart Rhythm, 10(3), 374–377. https://doi.org/10.1016/j.hrthm.2012.11.024
Maron, B., Haas, T., Doerer, J., Thompson, P., & Hodges, J. (2009). Comparison of U.S. and Italian experiences
with sudden cardiac deaths in young competitive athletes and implications for preparticipation screening strategies.
American Journal of Cardiology, 104(2), 276–280. https://doi.org/10.1016/j.amjcard.2009.03.037
Maron, B. J., Doerer, J. J., Haas, T. S., Tierney, D. M., & Mueller, F. O. (2009). Sudden deaths in young
competitive athletes analysis of 1866 deaths in the united states, 1980-2006. Circulation, 119(8), 1085–1092.
https://doi.org/10.1161/CIRCULATIONAHA.108.804617
Maron, B. J., Gardin, J. M., Flack, J. M., Gidding, S. S., Kurosaki, T. T., & Bild, D. E. (1995). Prevalence of
hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects
in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation, 92(4), 785–9.
https://doi.org/10.1161/01.cir.92.4.785
Maron, B. J., Haas, T. S., Murphy, C. J., Ahluwalia, A., & Rutten-ramos, S. (2014). Incidence and Causes of Sudden
Death in U . S . College Athletes. Journal of the American College of Cardiology, 63(16), 1636–1643.
https://doi.org/10.1016/j.jacc.2014.01.041
Maron, B. J., & Maron, M. S. (2013). Hypertrophic cardiomyopathy. The Lancet, 381(9862), 242–255.
https://doi.org/10.1016/S0140-6736(12)60397-3
Maron, B. J., Udelson, J. E., Bonow, R. O., Nishimura, R. A., Ackerman, M. J., Estes, M., … Maron, M. S. (2015).
AHA / ACC Scientific Statement Eligibility and Disqualification Recommendations for Competitive Athletes With
Cardiovascular Abnormalities : and Other Cardiomyopathies , and Myocarditis and American College of
Cardiology. Circulation, 132(22), 273–281. https://doi.org/https://doi.org/10.1161/CIR.0000000000000239
Maron, B. J., Zipes, D. P., & Kovacs, R. J. (2015). AHA/ACC Scientific Statement: Eligibility and Disqualification
Recommendations for Competitive Athletes With Cardiovascular Abnormalities. Circulation, 132(22), e256-61.
https://doi.org/10.1161/CIR.0000000000000236

Mitten, M. J., Zipes, D. P., Maron, B. J., Bryant, W. J., & Heart, A. (2015). Eligibility and Disqualification
Recommendations for Competitive Athletes With Cardiovascular Abnormalities : Task Force 15 : Legal Aspects of
Medical Eligibility and Disqualification Recommendations and American College of Cardiology. Circulation,
132(22), 346–350. https://doi.org/10.1161/CIR.0000000000000251
Mont, L., Pelliccia, A., Sharma, S., Biffi, A., Borjesson, M., Brugada Terradellas, J., … Domenico, C. (2017). Preparticipation cardiovascular evaluation for athletic participants to prevent sudden death : Position paper from the
EHRA and the EACPR , branches of the ESC . Endorsed by APHRS , HRS , and. European Journal of Preventive
Cardiology, 24(1), 41–69. https://doi.org/10.1177/2047487316676042
Napolitano, C., Priori, S.G., Schwartz, P.J. et al. (2005). Genetic testing in the long QT syndrome: development and
validation of an efficient approach to genotyping in clinical practice. JAMA., 294: 2975–2980.
O'Mahony, C., Jichi, F., Pavlou, M., Monserrat, L., Anastasakis, A., Rapezzi, C., ... & Omar, R. Z. (2014). A novel
clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). European
heart journal, 35(30), 2010-2020. https://doi.org/10.1093/eurheartj/eht439
Pelliccia, A., Fagard, R., Bjørnstad, H. H., Anastassakis, A., Arbustini, E., Assanelli, D., … Thiene, G. (2005).
Recommendations for competitive sports participation in athletes with cardiovascular disease : A consensus
document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise
Physiology and the Working Group of M. European Heart Journal, 26(14), 1422–1445.
https://doi.org/https://doi.org/10.1093/eurheartj/ehi325
Priori, S. G., Chairperson, H. R. S., Wilde, A. A., Chairperson, E., Horie, M., Chairperson, A., … Kannankeril, P.
(2013). HRS / EHRA / APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with
Inherited Primary Arrhythmia Syndromes. Heart Rhythm, 10(12), 1932–1963.
https://doi.org/10.1016/j.hrthm.2013.05.014
Schwartz, P. J., & Crotti, L. (2011). QTc behavior during exercise and genetic testing for the long-qt syndrome.
Circulation, 124(20), 2181–2184. https://doi.org/10.1161/CIRCULATIONAHA.111.062182
Schwartz, P. J., Priori, S. G., Spazzolini, C., & Moss, A. J. (2001). Genotype-phenotype correlation in the {longQT} syndrome. Circulation.
Schwartz, P. J., Stramba-Badiale, M., Crotti, L., Pedrazzini, M., Besana, A., Bosi, G., … Spazzolini, C. (2009).
Prevalence of the Congenital long-QT Syndrome. Circulation, 120(18), 1761–1767.
https://doi.org/10.1161/CIRCULATIONAHA.109.863209
Taggart, N. W., Haglund, C. M., Tester, D. J., & Ackerman, M. J. (2007). Diagnostic miscues in congenital long-QT
syndrome. Circulation, 115(20), 2613–2620. https://doi.org/10.1161/CIRCULATIONAHA.106.661082
Zheng, Z., Croft, J. B., Giles, W. H., & Mensah, G. a. (2001). Clinical Investigation and Reports Sudden Cardiac
Death in the United States , 1989 to 1998. Circulation., 2158–2163.
https://www.ncbi.nlm.nih.gov/pubmed/11684624

